Holen Sie sich die Stockscreener-App
17.12
0.29%
0.05
Handel nachbörslich:
17.30
0.18
+1.05%
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Nurix stock delivers 64% return after Fair Value spotted opportunity - Investing.com
NRIX Reiterated by Needham -- Price Target Maintained at $34 - GuruFocus
Needham & Company LLC Reaffirms Buy Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Nurix, BioNxt Solutions, Zealand Pharma: New Therapies Ignite the Imagination - news.financial
Strength seen in Nurix Therapeutics (NRIX): Can its 6.8% jump turn into more strength? - MSN
Nurix surges 43% on up to $3B cancer drug deal with Roche - MSN
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs - MSN
BTIG Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
H.C. Wainwright Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy - Investing News Network
Nurix (NRIX) presents updated Bexobrutideg data at EHA 2026 - grafa.com
H.C. Wainwright reiterates Nurix stock rating on Roche deal - Investing.com UK
Nurix reports updated clinical data for CLL drug candidate - Investing.com UK
Nurix Therapeutics Deal With Roche Is Worth Betting On (NASDAQ:NRIX) - Seeking Alpha
Nurix Highlights Promising Phase 1b Data for Bexobrutideg - TipRanks
Nurix Therapeutics reports Phase 1a/1b update: 83% ORR, 22.1-month median PFS; 600 mg RP2D well tolerated - TradingView
Nurix (NASDAQ: NRIX) shows high CLL response rates in bexobrutideg Phase 1 - Stock Titan
Nurix Therapeutics To Report Updated Phase 1A/B Results For Btk Degrader Bexobrutideg, Highlighting Durable Responses In Relapsed/Refractory Cll/Sll And Promising Activity In Earlier Lines Of Therapy - TradingView
Experimental BTK degrader sees 83% response in relapsed CLL - Stock Titan
NRIX Reiterates Buy Rating by HC Wainwright & Co. -- Price Targe - GuruFocus
Nurix Therapeutics' (NRIX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Amova Asset Management Americas Inc. Has $24.48 Million Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
NRIX Maintained by Truist Securities -- Price Target Raised to $32 - GuruFocus
Nurix Therapeutics Inc. (NRIX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market - Sahm
NRIX Maintained by BTIG -- Price Target Raised to $32 - GuruFocus
Nurix Therapeutics Price Target Raised to $32.00/Share From $30.00 by Truist Securities - Moomoo
Nurix Therapeutics (NASDAQ:NRIX) Sees Unusually-High Trading Volume After Analyst Upgrade - MarketBeat
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions - Seeking Alpha
BTIG Research Increases Nurix Therapeutics (NASDAQ:NRIX) Price Target to $32.00 - MarketBeat
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength? - Yahoo Finance
Jefferies raises Nurix stock price target on Roche partnership By Investing.com - Investing.com Australia
Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated DiseasesSlideshow (NASDAQ:NRIX) 2026-06-09 - Seeking Alpha
Nurix stock gets Outperform rating reiterated by RBC Capital By Investing.com - Investing.com Australia
Nurix Therapeutics Inc to Host Investor Update Call Transcript - GuruFocus
Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - MSN
Nurix Therapeutics (NRIX) Stock Soars 24% on Roche Collaboration Announcement - GuruFocus
Roche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics - MSN
NRIX Maintained by Wells Fargo -- Price Target Lowered to $25 - GuruFocus
NRIX Maintained by Jefferies -- Price Target Raised to $45 - GuruFocus
NRIX Maintained by Needham -- Price Target Raised to $34 - GuruFocus
Roche's $2.3 Billion Nurix Deal Sends Shares Moving - GuruFocus
Nurix signs 4th and largest partnership to develop BTK degrader - BioWorld News
Roche Partners with Nurix (NRIX) for $2.3 Billion Blood Cancer D - GuruFocus
Three Bay Area biotech startups ink big-company deals potentially totaling $5 billion - The Business Journals
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying - Investor's Business Daily
Roche and Nurix Therapeutics Announce Global Collaboration | PharmExec - Pharmaceutical Executive
Nurix Therapeutics (NRIX) Partners with Roche in $3B Collaborati - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Price Target Lowered to $25.00 at Wells Fargo & Company - MarketBeat
Jefferies Financial Group Issues Positive Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat
NRIX Stock Slides As Traders Parse Insider Filing - timothysykes.com
Jefferies raises Nurix stock price target on Roche partnership - Investing.com UK
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):